Deficits in executive function (self-regulatory mechanisms) have been linked with many childhood disorders including attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder, and conduct disorder. Executive functioning is typically assessed by individually administering performance-based measures in a clinical setting. However, performance-based methods are inefficient for school psychologists. A more feasibly implemented measure for applied settings is the Behavior Rating Inventory of Executive Function (BRIEF), but researchers have raised questions about the internal validity and the proposed factors. In this study, we examined the factor structure of the teacher form of the BRIEF in a sample of 2,044 general education elementary students and 131 teachers in a multilevel design. Results revealed support for a model with three factors at Level 1 and one general factor at Level 2. The results of our study do not support the current two-factor model of the published BRIEF protocol.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09297049.2011.594427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ethnic Differences in the Association Between Cognitive Performance and Informant-rated Cognitive Decline.
Am J Geriatr Psychiatry
December 2024
Department of Neurology (EMB, DAL, NG, DBZ, LBM), University of Michigan Medical School, Ann Arbor, MI; School of Public Health (RM, LBM), University of Michigan, Ann Arbor, MI.
Objectives: It is unknown whether cognitive test scores are equivalently associated with informant-rated cognitive decline across culturally and linguistically diverse older adults. We examined the association between cognitive domain scores on the Harmonized Cognitive Assessment Protocol (HCAP) and informant-rated cognitive decline in a harmonized population-based sample of older adults.
Design, Setting, And Participants: We combined data from the HCAP sub-study of the Health and Retirement Study (HRS; 2016) and the Brain Attack Surveillance in Corpus Christi-Cognitive (BASIC-C; 2018-2020) study.
A systematic review of neurocognition and social cognition in body dysmorphic disorder.
Aust N Z J Psychiatry
January 2025
Centre for Mental Health, Swinburne University of Technology, Melbourne, VIC, Australia.
Objective: Neurocognitive underpinnings are implicated in the aetiology and maintenance of body dysmorphic disorder (BDD); however, inconsistent findings across a range of neurocognitive domains suggest that a comprehensive synthesis of the literature using a hierarchical framework of neurocognition is needed.
Methods: A final search across OVID Medline, PsycNET, Scopus and Web of Science databases was conducted on 20 June 2024 to identify research that examined performance on behavioural tasks of objective neurocognition in BDD. Risk of bias was assessed using the Newcastle-Ottawa Scale.
Apolipoprotein E4 (APOE4) is the strongest genetic risk factor for sporadic Alzheimer's disease (AD). Individuals with one copy of APOE4 exhibit greater amyloid-beta (Aβ) deposition compared to noncarriers, an effect that is even more pronounced in APOE4 homozygotes. Interestingly, APOE4 carriers not only show more AD pathology but also experience more rapid cognitive decline, particularly in episodic memory.
View Article and Find Full Text PDFIs executive attention affected by environmental lighting conditions?
PLoS One
January 2025
MSH Medical School Hamburg, University of Applied Sciences and Medical University, Hamburg, Germany, Europe.
Bright daylight has various positive influences, such as the long-term synchronization of circadian rhythms and an associated alertness that creates optimal conditions for attentional performance. However, the short-term effects of light on attention have not yet been sufficiently researched. Studies of these short-term effects on selective attention also showed partly contradictory effects.
View Article and Find Full Text PDFAn Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.
JAMA Neurol
January 2025
Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
Article Synopsis
- Fall risk and cognitive impairment are common issues in Parkinson's disease, necessitating effective treatments.
- The study evaluated the safety and efficacy of TAK-071, a targeted medication, in individuals with Parkinson's who also experience these challenges.
- Despite not showing significant improvement in gait variability, TAK-071 was found to enhance cognitive function, marking a potential positive outcome for patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!